Table 3.

Hepatic resection [vs. transarterial chemoembolization (TACE)] and multivariate hazard ratios of overall survival with 95% CIs in Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC).

	N a	Not adjusted	Model I b	Model II a
Before PS matching	522/876	0.41 (0.33–0.52)	0.43 (0.34–0.55)	0.45 (0.35–0.58)
After MI	553/942	0.41 (0.37–0.46)	0.44 (0.35–0.56)	0.47 (0.37–0.60)
Minus (HR+AT) c	382/701	0.39 (0.31–0.51)	0.42 (0.32–0.55)	0.45 (0.34–0.60)
After PS matching	157/338	0.56 (0.41–0.77)	–	–

Numbers that do not add up to 942 are attributable to missing data.

PS, propensity score; MI, multiple imputation; HR, hepatic resection; AT, ablative therapy

^aThis model was adjusted for Child–Pugh class (A or B), diameter of main tumor (in centimeters), location of lesions (unilobar or bilobar), intrahepatic tumor number (three or less or more than three), LogAFP (in nanograms per milliliter), LDH (in units per liter), and LogPLT (10⁹/L).

^bThis model was adjusted for Child–Pugh class (A or B), diameter of main tumor (<5 or ≥5 cm), location of lesions (unilobar or bilobar), intrahepatic tumor number (three or less or more than three), and AFP (<25 or ≥25), LDH (<245 or ≥245), and PLT (<150 or ≥150) levels.

^cThis cohort excluded patients with HR and AT as second-line treatments after MI.